Follow The Filings

EIKN Eikon Therapeutics

Eikon Therapeutics earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -1.63 —
Rev — — —

Insider trades

Open-market buys and sales by EIKN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All EIKN insider trades
  • $52.2M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Column Group IV GP, LP 10% owner, +7 joint filers
    Buy
    $1M 89,200 shares at $11.56 New stake
    Traded Sep 3 Filed Sep 8
  2. Column Group IV GP, LP 10% owner, +7 joint filers
    Buy
    $38.1M 2,117,760 shares at $18.00 New stake
    Traded Feb 6 Filed Feb 9
  3. Kenneth C Frazier Director
    Buy
    $2M 111,111 shares at $18.00 New stake
    Traded Feb 4 Filed Feb 6
  4. Josh Wolfe Director
    Buy
    $5M 277,776 shares at $18.00 New stake
    Traded Feb 4 Filed Feb 6
  5. Foresite Capital Management IV, LLC 10% owner, +7 joint filers
    Buy
    $1M 55,555 shares at $18.00 +4.4% to stake
    Traded Feb 4 Filed Feb 6

Also filed in the last 12 months, not counted as buying or selling: 28 conversions.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 7.01,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
8-K 5.02
8-K 5.02
8-K 7.01,8.01,9.01
SCHEDULE 13G —
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G —
10-K
8-K 2.02,9.01
SCHEDULE 13G —
SCHEDULE 13D —
SCHEDULE 13G —
8-K 5.03,9.01
424B4
S-1/A
S-1

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.